How Ebola Virus Counters the Interferon System

Zoonoses and Public Health

Volumn 59, Issue SUPPL.2, 2012, Pages 116-131

  Kuhl A ^a   Pohlmann S ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

Author keywords

Ebola virus; IFITM; Interferon system; Tetherin; VP24; VP35

Indexed keywords

ALPHA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; JANUS KINASE 1; SMALL INTERFERING RNA; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; VIRUS PROTEIN; VP24 PROTEIN; VP35 PROTEIN;

ARTICLE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUMOYLATION; T LYMPHOCYTE; VIRUS GENOME; VIRUS TRANSMISSION;

ANIMALS; EBOLAVIRUS; HUMANS; INTERFERONS; VIRAL PROTEINS; VIRAL REGULATORY AND ACCESSORY PROTEINS; ZOONOSES;

EBOLA VIRUS; MUS;

EID: 84866033647     PISSN: 18631959     EISSN: 18632378     Source Type: Journal    
DOI: 10.1111/j.1863-2378.2012.01454.x     Document Type: Article

References (111)

1. Barrette, R. W., S. A. Metwally, J. M. Rowland, L. Xu, S. R. Zaki, S. T. Nichol, P. E. Rollin, J. S. Towner, W. J. Shieh, B. Batten, T. K. Sealy, C. Carrillo, K. E. Moran, A. J. Bracht, G. A. Mayr, M. Sirios-Cruz, D. P. Catbagan, E. A. Lautner, T. G. Ksiazek, W. R. White, and M. T. McIntosh, 2009: Discovery of swine as a host for the Reston ebolavirus. Science 325, 204-206.
2. Basler, C. F., X. Wang, E. Mühlberger, V. Volchkov, J. Paragas, H. D. Klenk, A. García-Sastre, and P. Palese, 2000: The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U.S.A. 97, 12289-12294.
3. Basler, C. F., A. Mikulasova, L. Martínez-Sobrido, J. Paragas, E. Mühlberger, M. Bray, H. D. Klenk, P. Palese, and A. García-Sastre, 2003: The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77, 7945-7956.
4. Baum, A., and A. García-Sastre, 2010: Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 38, 1283-1299.
5. Baum, A., and A. García-Sastre, 2011: Differential recognition of viral RNA by RIG-I. Virulence 2, 166-169.
6. Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman, 2002: Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195, 593-602.
7. Bivalkar-Mehla, S., J. Vakharia, R. Mehla, M. Abreha, J. R. Kanwar, A. Tikoo, and A. Chauhan, 2011: Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res. 155, 1-9.
8. Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, B. J. Ryan, J. L. Weyer, W. L. van der, E. Fikrig, D. J. Adams, R. J. Xavier, M. Farzan, and S. J. Elledge, 2009: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139, 1243-1254.
9. Bray, M., 2001: The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 1365-1373.
10. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins, 1998: A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651-661.
11. Cárdenas, W. B., Y. M. Loo, M. Gale Jr, A. L. Hartman, C. R. Kimberlin, L. Martínez-Sobrido, E. O. Saphire, and C. F. Basler, 2006: Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80, 5168-5178.
12. Carette, J. E., M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer, N. Mulherkar, A. I. Kuehne, P. J. Kranzusch, A. M. Griffin, G. Ruthel, P. Dal Cin, J. M. Dye, S. P. Whelan, K. Chandran, and T. R. Brummelkamp, 2011: Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature, 477, 340-343.
13. Cen, S., Z. G. Peng, X. Y. Li, Z. R. Li, J. Ma, Y. M. Wang, B. Fan, X. F. You, Y. P. Wang, F. Liu, R. G. Shao, L. X. Zhao, L. Yu, and J. D. Jiang, 2010: Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285, 16546-16552.
14. Chandran, K., N. J. Sullivan, U. Felbor, S. P. Whelan, and J. M. Cunningham, 2005: Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643-1645.
15. Chang, T. H., T. Kubota, M. Matsuoka, S. Jones, S. B. Bradfute, M. Bray, and K. Ozato, 2009: Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5, e1000493.
16. Côté, M., J. Misasi, T. Ren, A. Bruchez, K. Lee, C. M. Filone, L. Hensley, Q. Li, D. Ory, K. Chandran, and J. Cunningham, 2011: Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344-348.
17. Dolnik, O., V. Volchkova, W. Garten, C. Carbonnelle, S. Becker, J. Kahnt, U. Ströher, H. D. Klenk, and V. Volchkov, 2004: Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23, 2175-2184.
18. Dolnik, O., L. Kolesnikova, and S. Becker, 2008: Filoviruses: interactions with the host cell. Cell. Mol. Life Sci. 65, 756-776.
19. Donelan, N. R., C. F. Basler, and A. García-Sastre, 2003: A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 77, 13257-13266.
20. Douglas, J. L., K. Viswanathan, M. N. McCarroll, J. K. Gustin, K. Früh, and A. V. Moses, 2009: Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 83, 7931-7947.
21. Dubé, M., B. B. Roy, P. Guiot-Guillain, J. Binette, J. Mercier, A. Chiasson, and E. A. Cohen, 2010: Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6, e1000856.
22. Ebihara, H., A. Takada, D. Kobasa, S. Jones, G. Neumann, S. Theriault, M. Bray, H. Feldmann, and Y. Kawaoka, 2006: Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73.
23. Enterlein, S., K. L. Warfield, D. L. Swenson, D. A. Stein, J. L. Smith, C. S. Gamble, A. D. Kroeker, P. L. Iversen, S. Bavari, and E. Mühlberger, 2006: VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50, 984-993.
24. Erikson, E., T. Adam, S. Schmidt, J. Lehmann-Koch, B. Over, C. Goffinet, C. Harter, I. Bekeredjian-Ding, S. Sertel, F. Lasitschka, and O. T. Keppler, 2011: In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. U.S.A. 108, 13688-13693.
25. Fabozzi, G., C. S. Nabel, M. A. Dolan, and N. J. Sullivan, 2011: Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 85, 2512-2523.
26. Feng, Z., M. Cerveny, Z. Yan, and B. He, 2007: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 81, 182-192.
27. García, M. A., E. F. Meurs, and M. Esteban, 2007: The dsRNA protein kinase PKR: virus and cell control. Biochimie 89, 799-811.
28. García-Sastre, A., and C. A. Biron, 2006: Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312, 879-882.
29. George, C. X., Z. Li, K. M. Okonski, A. M. Toth, Y. Wang, and C. E. Samuel, 2009: Tipping the balance: antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products. J. Interferon Cytokine Res. 29, 477-487.
30. Goffinet, C., I. Allespach, S. Homann, H. M. Tervo, A. Habermann, D. Rupp, L. Oberbremer, C. Kern, N. Tibroni, S. Welsch, J. Krijnse-Locker, G. Banting, H. G. Kräusslich, O. T. Fackler, and O. T. Keppler, 2009: HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5, 285-297.
31. Goffinet, C., S. Homann, I. Ambiel, N. Tibroni, D. Rupp, O. T. Keppler, and O. T. Fackler, 2010: Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84, 4089-4094.
32. Groseth, A., H. Feldmann, and J. E. Strong, 2007: The ecology of Ebola virus. Trends Microbiol. 15, 408-416.
33. Gupta, R. K., P. Mlcochova, A. Pelchen-Matthews, S. J. Petit, G. Mattiuzzo, D. Pillay, Y. Takeuchi, M. Marsh, and G. J. Towers, 2009: Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U.S.A. 106, 20889-20894.
34. Haasnoot, J., W. de Vries, E. J. Geutjes, M. Prins, P. de Haan, and B. Berkhout, 2007: The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3, e86.
35. Haller, O., P. Staeheli, and G. Kochs, 2007: Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812-818.
36. Hammonds, J., J. J. Wang, H. Yi, and P. Spearman, 2010: Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 6, e1000749.
37. Han, Z., H. Boshra, J. O. Sunyer, S. H. Zwiers, J. Paragas, and R. N. Harty, 2003: Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77, 1793-1800.
38. Hartlieb, B., and W. Weissenhorn, 2006: Filovirus assembly and budding. Virology 344, 64-70.
39. Hartman, A. L., J. S. Towner, and S. T. Nichol, 2004: A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328, 177-184.
40. Hartman, A. L., J. E. Dover, J. S. Towner, and S. T. Nichol, 2006: Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80, 6430-6440.
41. Hartman, A. L., B. H. Bird, J. S. Towner, Z. A. Antoniadou, S. R. Zaki, and S. T. Nichol, 2008a: Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J. Virol. 82, 2699-2704.
42. Hartman, A. L., L. Ling, S. T. Nichol, and M. L. Hibberd, 2008b: Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 82, 5348-5358.
43. Hartman, A. L., J. S. Towner, and S. T. Nichol, 2010: Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 30, 161-177.
44. Hayman, D. T., P. Emmerich, M. Yu, L. F. Wang, R. Suu-Ire, A. R. Fooks, A. A. Cunningham, and J. L. Wood, 2010: Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS ONE 5, e11978.
45. Hoenen, T., A. Groseth, L. Kolesnikova, S. Theriault, H. Ebihara, B. Hartlieb, S. Bamberg, H. Feldmann, U. Ströher, and S. Becker, 2006: Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J. Virol. 80, 7260-7264.
46. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi, 2005: IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772-777.
47. Huang, Y., L. Xu, Y. Sun, and G. J. Nabel, 2002: The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol. Cell 10, 307-316.
48. Huang, I. C., C. C. Bailey, J. L. Weyer, S. R. Radoshitzky, M. M. Becker, J. J. Chiang, A. L. Brass, A. A. Ahmed, X. Chi, L. Dong, L. E. Longobardi, D. Boltz, J. H. Kuhn, S. J. Elledge, S. Bavari, M. R. Denison, H. Choe, and M. Farzan, 2011: Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7, e1001258.
49. Jia, B., R. Serra-Moreno, W. Neidermyer, A. Rahmberg, J. Mackey, I. B. Fofana, W. E. Johnson, S. Westmoreland, and D. T. Evans, 2009: Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5, e1000429.
50. Jiang, D., J. M. Weidner, M. Qing, X. B. Pan, H. Guo, C. Xu, X. Zhang, A. Birk, J. Chang, P. Y. Shi, T. M. Block, and J. T. Guo, 2010: Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J. Virol. 84, 8332-8341.
51. Jin, H., Z. Yan, B. S. Prabhakar, Z. Feng, Y. Ma, D. Verpooten, B. Ganesh, and B. He, 2010: The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J. Gen. Virol. 91, 352-361.
52. Jouvenet, N., S. J. Neil, M. Zhadina, T. Zang, Z. Kratovac, Y. Lee, M. McNatt, T. Hatziioannou, and P. D. Bieniasz, 2009: Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83, 1837-1844.
53. Kaletsky, R. L., J. R. Francica, C. Agrawal-Gamse, and P. Bates, 2009: Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 106, 2886-2891.
54. Kawaoka, Y., 2005: How Ebola virus infects cells. N. Engl. J. Med. 352, 2645-2646.
55. Kimberlin, C. R., Z. A. Bornholdt, S. Li, V. L. Woods Jr, I. J. MacRae, and E. O. Saphire, 2010: Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. U.S.A. 107, 314-319.
56. Kühl, A., C. Banning, A. Marzi, J. Votteler, I. Steffen, S. Bertram, I. Glowacka, A. Konrad, M. Stürzl, J. T. Guo, U. Schubert, H. Feldmann, G. Behrens, M. Schindler, and S. Pöhlmann, 2011a: The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204 (Suppl. 3), S850-S860.
57. Kühl, A., M. Hoffmann, M. A. Müller, V. J. Munster, M. Kiene, T. S. Tsegaye, G. Behrens, G. Herrler, H. Feldmann, C. Drosten, and S. Pöhlmann, 2011b: Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J. Infect. Dis. 204 (Suppl. 3), S840-9.
58. Kuhn, J. H., 2008: Filoviruses. A compendium of 40years of epidemiological, clinical, and laboratory studies. Arch. Virol. Suppl. 20, 13-360.
59. Kupzig, S., V. Korolchuk, R. Rollason, A. Sugden, A. Wilde, and G. Banting, 2003: Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4, 694-709.
60. Le Tortorec, A., and S. J. Neil, 2009: Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83, 11966-11978.
61. Lee, M. S., F. J. Lebeda, and M. A. Olson, 2009: Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly. J. Struct. Biol. 167, 136-144.
62. Leroy, E. M., B. Kumulungui, X. Pourrut, P. Rouquet, A. Hassanin, P. Yaba, A. Délicat, J. T. Paweska, J. P. Gonzalez, and R. Swanepoel, 2005: Fruit bats as reservoirs of Ebola virus. Nature 438, 575-576.
63. Leung, D. W., N. D. Ginder, D. B. Fulton, J. Nix, C. F. Basler, R. B. Honzatko, and G. K. Amarasinghe, 2009: Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. U.S.A. 106, 411-416.
64. Leung, D. W., K. C. Prins, D. M. Borek, M. Farahbakhsh, J. M. Tufariello, P. Ramanan, J. C. Nix, L. A. Helgeson, Z. Otwinowski, R. B. Honzatko, C. F. Basler, and G. K. Amarasinghe, 2010: Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17, 165-172.
65. Licata, J. M., R. F. Johnson, Z. Han, and R. N. Harty, 2004: Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78, 7344-7351.
66. Liu, S. Y., D. J. Sanchez, and G. Cheng, 2011: New developments in the induction and antiviral effectors of type I interferon. Curr. Opin. Immunol. 23, 57-64.
67. Lopez, L. A., S. J. Yang, H. Hauser, C. M. Exline, K. G. Haworth, J. Oldenburg, and P. M. Cannon, 2010: Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84, 7243-7255.
68. Lu, J., Q. Pan, L. Rong, W. He, S. L. Liu, and C. Liang, 2011: The IFITM proteins inhibit HIV-1 infection. J. Virol. 85, 2126-2137.
69. Mahanty, S., M. Gupta, J. Paragas, M. Bray, R. Ahmed, and P. E. Rollin, 2003: Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312, 415-424.
70. Mangeat, B., G. Gers-Huber, M. Lehmann, M. Zufferey, J. Luban, and V. Piguet, 2009: HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5, e1000574.
71. Mansouri, M., K. Viswanathan, J. L. Douglas, J. Hines, J. Gustin, A. V. Moses, and K. Früh, 2009: Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83, 9672-9681.
72. Mateo, M., S. P. Reid, L. W. Leung, C. F. Basler, and V. E. Volchkov, 2010: Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 84, 1169-1175.
73. McNatt, M. W., T. Zang, T. Hatziioannou, M. Bartlett, I. B. Fofana, W. E. Johnson, S. J. Neil, and P. D. Bieniasz, 2009: Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5, e1000300.
74. Mehedi, M., D. Falzarano, J. Seebach, X. Hu, M. S. Carpenter, H. J. Schnittler, and H. Feldmann, 2011: A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 85, 5406-5414.
75. Mitchell, R. S., C. Katsura, M. A. Skasko, K. Fitzpatrick, D. Lau, A. Ruiz, E. B. Stephens, F. Margottin-Goguet, R. Benarous, and J. C. Guatelli, 2009: Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5, e1000450.
76. Mühlberger, E., M. Weik, V. E. Volchkov, H. D. Klenk, and S. Becker, 1999: Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 2333-2342.
77. Neil, S. J., T. Zang, and P. D. Bieniasz, 2008: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451, 425-430.
78. NIAID, 2011: NIAID category A, B, and C priority pathogens. Available at: http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/pages/cata.aspx (accessed on 10 August 2011).
79. Ono, A., and E. O. Freed, 2001: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U.S.A. 98, 13925-13930.
80. Pardieu, C., R. Vigan, S. J. Wilson, A. Calvi, T. Zang, P. Bieniasz, P. Kellam, G. J. Towers, and S. J. Neil, 2010: The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6, e1000843.
81. Perez-Caballero, D., T. Zang, A. Ebrahimi, M. W. McNatt, D. A. Gregory, M. C. Johnson, and P. D. Bieniasz, 2009: Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139, 499-511.
82. Prins, K. C., W. B. Cárdenas, and C. F. Basler, 2009: Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83, 3069-3077.
83. Prins, K. C., J. M. Binning, R. S. Shabman, D. W. Leung, G. K. Amarasinghe, and C. F. Basler, 2010a: Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 84, 10581-10591.
84. Prins, K. C., S. Delpeut, D. W. Leung, O. Reynard, V. A. Volchkova, S. P. Reid, P. Ramanan, W. B. Cárdenas, G. K. Amarasinghe, V. E. Volchkov, and C. F. Basler, 2010b: Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 84, 3004-3015.
85. Radoshitzky, S. R., L. Dong, X. Chi, J. C. Clester, C. Retterer, K. Spurgers, J. H. Kuhn, S. Sandwick, G. Ruthel, K. Kota, D. Boltz, T. Warren, P. J. Kranzusch, S. P. Whelan, and S. Bavari, 2010: Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84, 10569-10580.
86. Reid, S. P., W. B. Cárdenas, and C. F. Basler, 2005: Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology, 341, 179-189.
87. Reid, S. P., L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle, V. E. Volchkov, S. T. Nichol, and C. F. Basler, 2006: Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80, 5156-5167.
88. Reid, S. P., C. Valmas, O. Martinez, F. M. Sanchez, and C. F. Basler, 2007: Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81, 13469-13477.
89. Sadler, A. J., and B. R. Williams, 2008: Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559-568.
90. Sakuma, T., T. Noda, S. Urata, Y. Kawaoka, and J. Yasuda, 2009: Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83, 2382-2385.
91. Sanchez, A., S. G. Trappier, B. W. Mahy, C. J. Peters, and S. T. Nichol, 1996: The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U.S.A. 93, 3602-3607.
92. Sauter, D., M. Schindler, A. Specht, W. N. Landford, J. Münch, K. A. Kim, J. Votteler, U. Schubert, F. Bibollet-Ruche, B. F. Keele, J. Takehisa, Y. Ogando, C. Ochsenbauer, J. C. Kappes, A. Ayouba, M. Peeters, G. H. Learn, G. Shaw, P. M. Sharp, P. Bieniasz, B. H. Hahn, T. Hatziioannou, and F. Kirchhoff, 2009: Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6, 409-421.
93. Schindler, C., D. E. Levy, and T. Decker, 2007: JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 20059-20063.
94. Schoggins, J. W., S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones, P. Bieniasz, and C. M. Rice, 2011: A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481-485.
95. Schumann, M., T. Gantke, and E. Muhlberger, 2009: Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 8993-8997.
96. Sekimoto, T., N. Imamoto, K. Nakajima, T. Hirano, and Y. Yoneda, 1997: Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. 16, 7067-7077.
97. Siegrist, F., M. Ebeling, and U. Certa, 2011: The small interferon-induced transmembrane genes and proteins. J. Interferon Cytokine Res. 31, 183-197.
98. Simmons, G., D. N. Gosalia, A. J. Rennekamp, J. D. Reeves, S. L. Diamond, and P. Bates, 2005: Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102, 11876-11881.
99. Swanepoel, R., P. A. Leman, F. J. Burt, N. A. Zachariades, L. E. Braack, T. G. Ksiazek, P. E. Rollin, S. R. Zaki, and C. J. Peters, 1996: Experimental inoculation of plants and animals with Ebola virus. Emerg. Infect. Dis. 2, 321-325.
100. Takada, A., C. Robison, H. Goto, A. Sanchez, K. G. Murti, M. A. Whitt, and Y. Kawaoka, 1997: A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 14764-14769.
101. Towner, J. S., T. K. Sealy, M. L. Khristova, C. G. Albariño, S. Conlan, S. A. Reeder, P. L. Quan, W. I. Lipkin, R. Downing, J. W. Tappero, S. Okware, J. Lutwama, B. Bakamutumaho, J. Kayiwa, J. A. Comer, P. E. Rollin, T. G. Ksiazek, and S. T. Nichol, 2008: Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4, e1000212.
102. Van Damme, N., D. Goff, C. Katsura, R. L. Jorgenson, R. Mitchell, M. C. Johnson, E. B. Stephens, and J. Guatelli, 2008: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252.
103. Volchkov, V. E., S. Becker, V. A. Volchkova, V. A. Ternovoj, A. N. Kotov, S. V. Netesov, and H. D. Klenk, 1995: GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214, 421-430.
104. Volchkov, V. E., H. Feldmann, V. A. Volchkova, and H. D. Klenk, 1998: Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. U.S.A. 95, 5762-5767.
105. Volchkova, V. A., H. D. Klenk, and V. E. Volchkov, 1999: Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 265, 164-171.
106. Wahl-Jensen, V. M., T. A. Afanasieva, J. Seebach, U. Ströher, H. Feldmann, and H. J. Schnittler, 2005: Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79, 10442-10450.
107. Watanabe, R., G. P. Leser, and R. A. Lamb, 2011: Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 417(1), 50-56.
108. Weidner, J. M., D. Jiang, X. B. Pan, J. Chang, T. M. Block, and J. T. Guo, 2010: Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84, 12646-12657.
109. Wool-Lewis, R. J., and P. Bates, 1998: Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72, 3155-3160.
110. Yondola, M. A., F. Fernandes, A. Belicha-Villanueva, M. Uccelini, Q. Gao, C. Carter, and P. Palese, 2011: Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J. Virol. 85, 2480-2491.
111. Yount, J. S., B. Moltedo, Y. Y. Yang, G. Charron, T. M. Moran, C. B. Lopéz, and H. C. Hang, 2010: Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 6, 610-614.